268 related articles for article (PubMed ID: 31571830)
1. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
Tang Z; Feng W; Yang Y; Wang Q
Drug Des Devel Ther; 2019; 13():3281-3290. PubMed ID: 31571830
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity.
Cai W; Geng C; Jiang L; Sun J; Chen B; Zhou Y; Yang B; Lu H
Pharm Dev Technol; 2020 Jun; 25(5):640-648. PubMed ID: 32028816
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor efficacy of folate modified PLGA-based nanoparticles for the co-delivery of drugs in ovarian cancer.
Li S; Li X; Ding J; Han L; Guo X
Drug Des Devel Ther; 2019; 13():1271-1280. PubMed ID: 31114163
[No Abstract] [Full Text] [Related]
4. Externally Triggered Novel Rapid-Release Sonosensitive Folate-Modified Liposomes for Gemcitabine: Development and Characteristics.
Omar MM; Hasan OA; Zaki RM; Eleraky NE
Int J Nanomedicine; 2021; 16():683-700. PubMed ID: 33536754
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
[TBL] [Abstract][Full Text] [Related]
6. A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.
Li PW; Luo S; Xiao LY; Tian BL; Wang L; Zhang ZR; Zeng YC
Acta Pharmacol Sin; 2019 Nov; 40(11):1448-1456. PubMed ID: 31015736
[TBL] [Abstract][Full Text] [Related]
7. Delivery of folic acid-modified liposomal curcumin for targeted cervical carcinoma therapy.
Wang WY; Cao YX; Zhou X; Wei B
Drug Des Devel Ther; 2019; 13():2205-2213. PubMed ID: 31308632
[No Abstract] [Full Text] [Related]
8. A Novel Delivery System of RGD-HSA Loaded GEM/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy.
Ma T; Jiang JL; Qi WX; Chen JY; Xu HP
Drug Des Devel Ther; 2022; 16():2395-2406. PubMed ID: 35923931
[TBL] [Abstract][Full Text] [Related]
9. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer.
Cosco D; Bulotta A; Ventura M; Celia C; Calimeri T; Perri G; Paolino D; Costa N; Neri P; Tagliaferri P; Tassone P; Fresta M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1009-20. PubMed ID: 19263052
[TBL] [Abstract][Full Text] [Related]
10. Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation.
Jiang K; Shen M; Xu W
Int J Nanomedicine; 2018; 13():2561-2569. PubMed ID: 29731631
[TBL] [Abstract][Full Text] [Related]
11. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo.
Yalcin TE; Ilbasmis-Tamer S; Takka S
Int J Pharm; 2020 Apr; 580():119246. PubMed ID: 32205141
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine.
Dubey RD; Alam N; Saneja A; Khare V; Kumar A; Vaidh S; Mahajan G; Sharma PR; Singh SK; Mondhe DM; Gupta PN
Int J Pharm; 2015 Aug; 492(1-2):80-91. PubMed ID: 26165611
[TBL] [Abstract][Full Text] [Related]
14. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
15. Development of Gemcitabine Loaded PLGA/Lecithin Nanoparticles for Non-Small Cell Lung Cancer Therapy.
Esim O; Ozkan CK; Sarper M; Savaser A; Ozkan Y
Curr Drug Deliv; 2020; 17(7):622-628. PubMed ID: 32394837
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific delivery of gemcitabine with activatable liposomes.
Tucci ST; Kheirolomoom A; Ingham ES; Mahakian LM; Tam SM; Foiret J; Hubbard NE; Borowsky AD; Baikoghli M; Cheng RH; Ferrara KW
J Control Release; 2019 Sep; 309():277-288. PubMed ID: 31301340
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
Karavana SY; Şenyiğit ZA; Çalışkan Ç; Sevin G; Özdemir Dİ; Erzurumlu Y; Şen S; Baloğlu E
Drug Des Devel Ther; 2018; 12():1959-1975. PubMed ID: 29997433
[TBL] [Abstract][Full Text] [Related]
18. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
[TBL] [Abstract][Full Text] [Related]
19. Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging.
Affram K; Udofot O; Singh M; Krishnan S; Reams R; Rosenberg J; Agyare E
PLoS One; 2017; 12(9):e0185116. PubMed ID: 28934281
[TBL] [Abstract][Full Text] [Related]
20. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
